Evaluating patients with clinical features or at-risk for systemic lupus erythematosus (SLE).The levels of antibodies to dsDNA may fluctuate with SLE disease activity. Increasing antibody levels may be associated with flares while decline or negative results may indicate response to treatment or disease remission.